Aldatu Biosciences

It is with deep sadness that we pass along news of the sudden death of our friend, mentor, and Scientific Advisory Board member, Prof. Mark Wainberg. Mark was one of the earliest supporters of Aldatu and our efforts to bring PANDAA to patients, and for that he will always have our gratitude. His passing represents a tremendous loss for not only our company, but the entire HIV community. Our hearts and thoughts are with his family and colleagues today.

Aldatu Biosciences has been awarded a Direct-to-Phase II Small Business Innovation Research (SBIR) grant for approximately $3,000,000 over three years from the National Institute of Allergy and Infectious Disease (NIAID) at the National Institutes of Health (NIH). The award will fund the continued advancement of the company’s proprietary platform technology, PANDAA, and its specific application to HIV genotyping.

Aldatu recently received a program-related investment (PRI) from CH Innovations (a subsidiary of the Charles H. Hood Foundation), a Boston based organization whose mission is to fund entrepreneurial efforts to improve the health and quality of life for children around the world.

Aldatu Biosciences, Inc. today announced that it has entered into a licensing agreement with Harvard University’s Office of Technology Development based on intellectual property developed in the laboratory of Professor Myron (Max) Essex, DVM, PhD, at the Harvard T.H. Chan School of Public Health.

Q&A: A New Test For Drug-Resistant HIV Breaks All the Scientific Rules A former postdoctoral fellow with the Harvard T.H. Chan School of Public Health AIDS Initiative, virologist Iain MacLeod in 2014 cofounded Aldatu Biosciences, which provides sensitive and cost-effective diagnostics to detect drug resistance in antiretroviral treatments for HIV.

Washington, DC, 18th September 2015 (download press release .pdf) AdvaMed 2015: The MedTech Conference, the leading gathering of medical technology professionals in North America, has awarded 48 scholarships to early and development stage medical device, diagnostic and health IT companies to present at the conference in San Diego from October 5-7. “Exposure at conferences like AdvaMed 2015 is crucial for early …

Aldatu was selected to participate in the Innovation Challenge as part of the Redefining Early State Investments (RESI) Conference being held in Boston on September 16th, 2015. Aldatu will join 29 other innovative life science companies in therapeutics, diagnostics, medical devices, and healthcare IT tracks in an exhibition-style presentation format throughout the day-long conference.

Cambridge, MA, 12th March 2015 (download press release .pdf) Aldatu Biosciences, a novel diagnostics platform company focused on improving HIV patient care globally, today announced it has been awarded a Direct-to-Phase II Small Business Innovation Research (SBIR) grant for approximately $1,500,000 over two years. Supported by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health …

A $250,000 prize to Aldatu Biosciences announced today from the Verizon Powerful Answers Awards stands to fundamentally change the way HIV treatment is delivered across the world by advancing the development of Aldatu’s affordable HIV drug resistance diagnostic, PANDAA™ HIV6.